Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (141-150 of 250) with videos related to

Pageof 25
Sort By:
Hematological Oncology|September 9, 2016
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism arrayRamón García-Sanz, Luis Antonio Corchete, Miguel Alcoceba, et al.
Blood|June 20, 2015
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonalityJoaquín Martínez-López, Bruno Paiva, Lucía López-Anglada, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.
Blood|March 21, 2014
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaJoaquin Martinez-Lopez, Juan J Lahuerta, François Pepin, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Haematologica|July 29, 2010
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Haematologica|February 12, 2002
Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trialJosep-Maria Ribera, Juan-José Ortega, Albert Oriol, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Pageof 25

Showing results (141-150 of 250) with videos related to

Sort By:
Pageof 25
Hematological Oncology|September 9, 2016
Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism arrayRamón García-Sanz, Luis Antonio Corchete, Miguel Alcoceba, et al.
Blood|June 20, 2015
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonalityJoaquín Martínez-López, Bruno Paiva, Lucía López-Anglada, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.
Blood|March 21, 2014
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaJoaquin Martinez-Lopez, Juan J Lahuerta, François Pepin, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Haematologica|July 29, 2010
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Haematologica|February 12, 2002
Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trialJosep-Maria Ribera, Juan-José Ortega, Albert Oriol, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
Pageof 25